Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Preferred Stock Liabilities (2016 - 2025)

Enanta Pharmaceuticals' Preferred Stock Liabilities history spans 13 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Preferred Stock Liabilities fell 2.89% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 2.89%, while the annual FY2025 figure was $1.3 million, 2.89% down from the prior year.
  • Preferred Stock Liabilities reached $1.3 million in Q4 2025 per ENTA's latest filing, roughly flat from $1.3 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $1.5 million in Q3 2021 to a low of $1.3 million in Q3 2025.
  • Average Preferred Stock Liabilities over 5 years is $1.4 million, with a median of $1.4 million recorded in 2022.
  • The largest YoY upside for Preferred Stock Liabilities was 1.83% in 2021 against a maximum downside of 9.15% in 2021.
  • A 5-year view of Preferred Stock Liabilities shows it stood at $1.5 million in 2021, then decreased by 5.51% to $1.4 million in 2022, then changed by 0.0% to $1.4 million in 2023, then dropped by 5.13% to $1.3 million in 2024, then fell by 2.89% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Preferred Stock Liabilities are $1.3 million (Q4 2025), $1.3 million (Q3 2025), and $1.3 million (Q2 2025).